Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Diabetes (August 2016)

Posted by Matt Breese on Aug 19, 2016

Find me on:

MMIT's team analyzes the market access landscape for diabetes treatments in our most recent Reality Check. The following brief highlights some of our key takeaways from the piece.

According to our recent payer coverage analysis for diabetes treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for diabetes treatments shows coverage variation across commercial, health exchange and medicare part D formularies. Health exchange plans are the most restrictive with well over half of lives either not covered entirely or restricted by PA/step therapies.


Source: MMIT data as of Q3 2016

Trends: One trend is the the increasing prices for diabetes pharmaceuticals. Recent data from CMS shows that diabetes treatment price increases year-over-year are among the highest in the nation, which inspires physicians to pay closer attention to market access and efficacy for their patients.

To read the full Reality Check on MS treatments with key findings on clinical characteristics, MS drug market access and payer coverage, please click on the button below: 



View Reality Check

Topics: Specialty, Market Access, Branding & Marketing